# EDGAR Filing Document

**Accession Number:** 0001786511
**File Stem:** 0001104659-23-022230
**Filing Date:** 2023-2
**Character Count:** 14306
**Document Hash:** f6f8d0f7d2ae20f437a0263680f72875
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-022230.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001104659-23-022230

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230215

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AnPac Bio-Medical Science Co., Ltd.
- **CENTRAL INDEX KEY:** 0001786511
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** D8

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39137
- **FILM NUMBER:** 23633732

**BUSINESS ADDRESS:**
- **STREET 1:** 801 BIXING STREET
- **STREET 2:** BIHU COUNTY
- **CITY:** LISHUI, ZHEJIANG PROVINCE
- **STATE:** F4
- **ZIP:** 323006
- **BUSINESS PHONE:** 8657820516666

**MAIL ADDRESS:**
- **STREET 1:** 801 BIXING STREET
- **STREET 2:** BIHU COUNTY
- **CITY:** LISHUI, ZHEJIANG PROVINCE
- **STATE:** F4
- **ZIP:** 323006

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2023**

**Commission File Number: 001-39137**

**AnPac Bio-Medical Science Co., Ltd.**

**801 Bixing Street, Bihu County**

**Lishui, Zhejiang Province 323006**

**The People's Republic of China**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

Material Definitive Agreement

On January 28, 2023, AnPac Bio-Medical Science Co., Ltd. (the "Registrant" or the "Company"), through a subsidiary, Fresh2 Technology Inc. ("Fresh2"), entered into a Share Purchase Agreement (the "GISN Agreement") to acquire GISN (HK) LIMITED, a company incorporated under the laws of Hong Kong ("GISN"). GISN provides professional technical solutions, outsourcing consulting services and specialized smart restaurant solutions to regional catering service clients through a specialized internet platform that integrates service modules such as cross-currency payments, enterprise resource planning and marketing SaaS.

Pursuant to the GISN Agreement, Fresh2 agreed to purchase all the issued and outstanding equity interests in GISN in consideration of US$1,700,000, payable in the form of 8,785,530 Class A ordinary shares of the Company. The GISN Agreement closed on February 2, 2023 when 100% ownership of GISN was transferred to Fresh2 and 8,785,530 Class A ordinary shares of the Company were issued to the sellers.

On February 10, 2023, the Company issued a press release announcing the entry into and closing of the GISN Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information under Exhibit 99.1 is deemed "furnished" and not "filed" under Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The information in this Current Report on Form 6-K, including Exhibit 99.1, may contain forward-looking statements based on management's current expectations and projections, which are intended to qualify for the safe harbor of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The statements contained herein that are not historical facts are considered "forward-looking statements." Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, statements regarding the efficacy of investment in research and development are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the effect of political, economic, and market conditions and geopolitical events; the Company's ability to maintain its Nasdaq listing, legislative and regulatory changes that affect our business; the availability of funds and working capital; the actions and initiatives of current and potential competitors; investor sentiment; and our reputation. The Company not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. A number of these risks along with additional discussion of forward-looking statements, are set forth in the Company's Annual Report on Form 20-F and other reports filed with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the COVID19 virus and the impact it will have on the Company's operations, global supply chains and economic activity in general.

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm236204d1_ex99-1.htm) | [Press Release dated February 15, 2023](tm236204d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| AnPac Bio-Medical Science Co., Ltd. | AnPac Bio-Medical Science Co., Ltd. |
| By: | /s/ Haohan Xu |
| Name: | Haohan Xu |
| Title: | Co-Chief Executive Officer |

---

Dated: February 15, 2023

## Exhibit 99.1

**Exhibit 99.1**

**AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider** 

New York, NY, Feb. 15 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commerce operations.

GISN is a highly qualified service provider with extensive experience in providing technical support for enterprises wishing to transform from a traditional operating model to a digital operating model. GISN provides customized technical solutions for Web3 and payment fields and comprehensive management from design, R&D, testing, operating and maintenance. With a solid track record, GISN has developed a smart restaurant internet platform that integrates service modules of cross-currency payment, ERP and marketing on a SaaS basis. GISN is committed to providing secure, highly efficient and low-cost services to its customers.

The acquisition is pursuant to a stock purchase agreement the Company entered into on January 28, 2023, whereby it agreed to purchase 100% of the issued and outstanding equity interest of GISN in consideration of $1,700,000, payable in the form of newly issued Class A ordinary shares of the Company.

Mr. Haohan Xu, the Co-CEO of the Company, commented, "We are pleased to announce closing of this acquisition and expect to see the positive impact of GISN's expertise on the development of our e-commerce business. This transaction is the result of a deliberate and thoughtful process. We evaluated the transaction against our standalone prospects in the current macroeconomic climate and determined that the compelling capabilities of GISN will enhance our Company's prospects. Leveraging on the competitive strengths of GISN, we believe that we are well-positioned to enter and expand our e-commerce business efficiently. We believe this transaction will create long-term values for our shareholders."

**About GISN (HK) LIMITED** 

GISN (HK) LIMITED is a technical solution and outsourcing consulting service provider focused on the digital, internet, and Web3 transformation of start-ups and traditional enterprises. GISN focuses on highly professional and value-added fields including Web3 and payment. With experience in the internet and Web3 fields, GISN has a deep understanding of finance, catering and medical care and helps customers realize the rapid development of their business platform which enables customers to improve their operating efficiency, income and security. GISN provides customized business platform consulting services with its senior industry experts, experienced technical experts and reliable security architecture.

**About AnPac Bio**-**Medical Science Co., Ltd.** 

AnPac Bio-Medical Science Co., Ltd.is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of June 30, 2022. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. The Company intends to enter the business-to-business e-commerce food business with the formation of its wholly-owned subsidiary Fresh2 Technology Inc and the acquisition of Fresh2 Ecommerce Inc.

For more information, please visit: <u>https://www.Anpacbio.com</u>.

**For investor and media inquiries, please contact:**

Ascent Investor Relations LLC<br> Tina Xiao<br> Phone: +1-917-609-0333 (U.S.)<br> Email: <u>tina.xiao@ascent-ir.com</u>

**Safe Harbor Statement**

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules including maintain our listing on the Nasdaq Capital Market, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. A number of these risks along with additional discussion of forward-looking statements, are set forth in the Company's Annual Report on Form 20-F and other reports filed with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the COVID19 virus and the impact it will have on the Company's operations, global supply chains and economic activity in general. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.